To ask the Secretary of State for Health, if he will make it his policy to compensate (a) the dependants of those who have died from hepatitis due to infected blood products and (b) those who contracted hepatitis by such means, but recovered after treatment.

To ask the Secretary of State for Health, if he will make it his policy to compensate (a) the dependants of those who have died from hepatitis due to infected blood products and (b) those who contracted hepatitis by such means, but recovered after treatment.

To ask the Secretary of State for Health, how many people suffering from haemophilia have (a) died and (b) suffered illness as a result of contaminated blood products from the NHS in each of the last five years; and if he will make a statement. - Includes figures and table.

To ask the Secretary of State for Health, how many people suffering from haemophilia have (a) died and (b) suffered illness as a result of contaminated blood products from the NHS in each of the last five years; and if he will make a statement. - Includes figures and table.

To ask the Secretary of State for Health, if he will make a statement on the steps that he is taking to ensure that contaminants are not present in NHS blood products.

To ask the Secretary of State for Health, if he will make a statement on the steps that he is taking to ensure that contaminants are not present in NHS blood products.

To ask the Secretary of State for Health, what research his Department (a) has commissioned and (b) is evaluating in order to determine the level of compensation for people infected with hepatitis C due to infected blood products; and if he will make a statement.

To ask the Secretary of State for Health, what research his Department (a) has commissioned and (b) is evaluating in order to determine the level of compensation for people infected with hepatitis C due to infected blood products; and if he will make a statement.

To ask the Secretary of State for Northern Ireland, pursuant to the Answer of 20 October 2003, 411 c420W, on anti-coagulants, what effect the results of the home use trial of coagulometers by Roche Ltd. will have on current practice.

To ask the Secretary of State for Northern Ireland, pursuant to the Answer of 20 October 2003, 411 c420W, on anti-coagulants, what effect the results of the home use trial of coagulometers by Roche Ltd. will have on current practice.

To ask the Secretary of State for Health, if he will make a statement on progress in working out the details in relation to his announcement on 29th August that he would establish a financial assistance scheme for people infected with hepatitis C as a result of being given blood...

To ask the Secretary of State for Health, if he will make a statement on progress in working out the details in relation to his announcement on 29th August that he would establish a financial assistance scheme for people infected with hepatitis C as a result of being given blood...

Further to the Written Answer by the Lord Warner on 8 September 2003, 652 c66WA, whether male donors means male "untransfused" donors; what was the evidence that the switch to male (untransfused) donors would reduce the incidence of transfusion-related acute lung injury (as reported in the 2001-02 Serious Hazards of...

Further to the Written Answer by the Lord Warner on 8 September 2003, 652 c66WA, whether male donors means male "untransfused" donors; what was the evidence that the switch to male (untransfused) donors would reduce the incidence of transfusion-related acute lung injury (as reported in the 2001-02 Serious Hazards of...

Further to the Written Answer by the Lord Warner on 6 October 2003, 653 c42WA, whether they will take steps to establish at the earliest possible date the number of haemophilia patients who have been informed by the National Health Service that blood products from donors diagnosed with vCJD were...

Further to the Written Answer by the Lord Warner on 6 October 2003, 653 c42WA, whether they will take steps to establish at the earliest possible date the number of haemophilia patients who have been informed by the National Health Service that blood products from donors diagnosed with vCJD were...

To ask the Secretary of State for Northern Ireland, what plans he has to make coagulometers more widely available in Northern Ireland for home monitoring of international normalised ratios by patients on warfarin. - There are no plans at present to make coagulometers available for home use on the HPSS.

To ask the Secretary of State for Northern Ireland, what plans he has to make coagulometers more widely available in Northern Ireland for home monitoring of international normalised ratios by patients on warfarin. - There are no plans at present to make coagulometers available for home use on the HPSS.

To ask the Secretary of State for Northern Ireland, what estimate he has made of the cost of monitoring international normalised ratio levels of patients in Northern Ireland on warfarin in the last year for which figures are available. - Disproportionate cost.

To ask the Secretary of State for Northern Ireland, what estimate he has made of the cost of monitoring international normalised ratio levels of patients in Northern Ireland on warfarin in the last year for which figures are available. - Disproportionate cost.

To ask the Secretary of State for Northern Ireland, how many coagulometers were provided through the health service in Northern Ireland for patients to monitor international normalised ratio levels at home, in the last year for which figures are available.

To ask the Secretary of State for Northern Ireland, how many coagulometers were provided through the health service in Northern Ireland for patients to monitor international normalised ratio levels at home, in the last year for which figures are available.

Following the recent publication of a letter by G. F. Reidler in Vox Sanguinis, which identifies deaths as a result of non-infective complications of blood transfusions, why they have not taken steps to prevent avoidable deaths and serious morbidity. [HL 4251].

Following the recent publication of a letter by G. F. Reidler in Vox Sanguinis, which identifies deaths as a result of non-infective complications of blood transfusions, why they have not taken steps to prevent avoidable deaths and serious morbidity. [HL 4251].

To ask the Secretary of State for Health, if he will make a statement on the impact on the NHS of catheter-associated infection in relation to vancomycin resistant enterocci. - Information not available centrally.

To ask the Secretary of State for Health, if he will make a statement on the impact on the NHS of catheter-associated infection in relation to vancomycin resistant enterocci. - Information not available centrally.

Further to the Written Answer by Lord Warner to the Written Question 8 September 2003, 652 c64WA [HL 4217] how many haemophilia patients have been informed by the National Health Service that blood products from donors diagnosed with vCJD were used in their treatment. [HL 4257]. - Inc no figures.

Further to the Written Answer by Lord Warner to the Written Question 8 September 2003, 652 c64WA [HL 4217] how many haemophilia patients have been informed by the National Health Service that blood products from donors diagnosed with vCJD were used in their treatment. [HL 4257]. - Inc no figures.